Loading organizations...

§ Venture Capital · Wilmington, NC, USA
Private investment firm that primarily invests in private healthcare companies, with founder Fred Eshelman on portfolio boards.
Key people at Eshelman Ventures.
Eshelman Ventures was founded by Fred Eshelman (Founder).
Eshelman Ventures is a Wilmington, North Carolina-based investment firm that primarily allocates capital to private healthcare companies. The firm leverages the extensive pharmaceutical industry experience of its leadership, who previously held prominent roles at major organizations including Pharmaceutical Product Development, Furiex Pharmaceuticals, and The Medicines Company. Prior to establishing the investment vehicle, the firm's leadership successfully built and exited multiple healthcare enterprises, including the sale of PPD to private equity investors in 2011 and the acquisition of Furiex Pharmaceuticals by Forest Labs in 2014. The organization maintains close ties to academic research initiatives, highlighted by a $100 million philanthropic commitment that launched Eshelman Innovation at the University of North Carolina. Operating as a private investment vehicle that frequently takes active board positions within its portfolio companies, Eshelman Ventures was founded by healthcare executive Fred Eshelman.
Eshelman Ventures was founded by Fred Eshelman (Founder).
Key people at Eshelman Ventures.
Eshelman Ventures has 2 tracked investments across 2 companies. The latest tracked deal is $75.0M Series B in Kinnate Biopharma in December 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2019 | Kinnate Biopharma | $75.0M Series B | — | AMR Action Fund, Foresite Capital, General Atlantic, HBM Partners, OrbiMed, SR ONE, The Column Group, Versant Ventures, Vivo Capital, Nextech Invest, Vida Ventures |
| May 1, 2016 | G1 Therapeutics | $47.0M Series C | Bihua Chen | Catalio Capital, Hatteras Venture Partners, Ryan Allis, AJU IB Investment, Cowen Private Investments, Franklin Templeton, Lumira Ventures, Medimmune Ventures, Mountain Group Partners, RA Capital Management, Rock Springs Capital, Tavistock Group |